Preclinical characterisation of antibody-drug conjugates - ADME perspective
23 August 2021
Antibody drug conjugate (ADC) comprise of a monoclonal antibody and cytotoxic payload conjugated by a linker. The antibody is purposed to deliver the payload to the target located on the cancer cell. The payload is typically a highly potent small molecule, which should be released from the carrier antibody inside the tumour cell. The number of the released but differently conjugated small molecules is affected by the used conjugation method and strategy.Read more
MIST evaluation toolbox – what is in there? Part 2
15 June 2021
In Part 1, Dr Johanna Haglund (Head of Safety Metabolism) described the first steps to be taken in the Metabolites in Safety Testing evaluation (MIST) and in this second part, she will elaborate how to proceed after in vitro cross species comparison between human and safety species.Read more
A new e-book is out and it’s all about biologics!
1 June 2021
Admescope’s e-book series was launched in 2017 and the six e-books published over couple of years cover comprehensively ADME-tox topics for small molecules, the latest one being about Safety Metabolism in 2019. We have been delighted by the received positive feedback and huge interest towards our e-books.Read more
10 years of Admescope
26 March 2021
Admescope´s 10th anniversary was celebrated on 16th March 2021. A lot has happened over the years. So, let´s start up a time machine and look back to the past!Read more
MIST evaluation toolbox – what is in there? Part 1
5 March 2021
Safety testing of drug metabolites is often discussed as ”MIST (metabolites in safety testing) evaluation”, according the guidelines set up by the FDA and ICH. The MIST evaluation is a multi-step approach to ensure human metabolites are safety tested. This can be seen as a MIST toolbox, where each tool is used in a pragmatic approach at the time they become possible and available. It is all about understanding the risk for potential metabolite safety issues early in the development of a candidate drug. In this blog post, Dr Johanna Haglund (Head of Safety Metabolism) sheds light on the metabolites in safety testing theme and how to start the MIST evaluation.Read more
